NoBACZ Healthcare, a spinout company from the University of Cambridge developing novel technologies to treat wounds in livestock, has raised £4.8m in a new funding round.
The new investment will support the development and commercialisation of the company’s patented “liquid bandage technology”, a new system for treating wounds on animals that it claims are healthier and more effective.
Founded by researchers from the University of Cambridge’s Department of Veterinary Medicine, the NoBACZ Healthcare team were exploring how to solve dermatological diseases that were painful for livestock and costly for farmers.
This research led to the creation of its signature liquid bandage, a waterproof protective layer applied as a gel, dip or spray that the company claims can seal away bacteria and drastically reduce the risk of wound infection present in the use of traditional bandages.
“We founded NoBACZ Healthcare with the goal of transforming healthcare solutions for a more sustainable future whilst reducing antibiotic use,” said Dr Jonathan Powell, co-founder and chief executive of NoBACZ Healthcare.
“This new funding will fuel our expansion as we broaden our global product reach, launch our new range of products for the equine industry and continue to develop innovative veterinary healthcare solutions.”
Though primarily focused on veterinary healthcare solutions, Powell said the team was also looking into its “human product opportunity”.
The funding round was led by The Yield Lab and included participation from Adjuvo, ACF Investors, the University of Cambridge, Parkwalk, The FSE Group, and Cambridge Enterprise Ventures.
“The team has consistently impressed us with their vision, execution, and commitment to transforming animal healthcare with sustainable, antibiotic-free solutions,” said Gentiane Gorlier, a general partner at The Yield Lab.
“Leading this round reflects our confidence in NoBACZ’s leadership and technology, and we believe the company is poised for significant global impact.”
The company is active in the UK, Europe, the US, Australia and New Zealand.